$148 Billion is the total value of ACUTA CAPITAL PARTNERS, LLC's 64 reported holdings in Q4 2014. The portfolio turnover from Q3 2014 to Q4 2014 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IWM | New | ISHARES TRput | $27,513,000 | – | 230,000 | +100.0% | 18.59% | – |
| FOLD | New | AMICUS THERAPEUTICS | $13,584,000 | – | 1,632,720 | +100.0% | 9.18% | – |
| QQQ | New | POWERSHARES QQQ TRUSTput | $7,228,000 | – | 70,000 | +100.0% | 4.88% | – |
| ALIM | New | ALIMERA SCIENCES | $5,855,000 | – | 1,056,809 | +100.0% | 3.96% | – |
| PTX | New | PERNIX THERAPEUTICS HLDGS | $5,672,000 | – | 604,075 | +100.0% | 3.83% | – |
| BEAT | New | BIOTELEMETRY | $4,853,000 | – | 483,872 | +100.0% | 3.28% | – |
| CEMP | New | CEMPRAcall | $3,874,000 | – | 164,800 | +100.0% | 2.62% | – |
| New | EXELIXIS INCnote 4.250% | $3,613,000 | – | 6,474,000 | +100.0% | 2.44% | – | |
| LMAT | New | LEMAITRE VASCULAR | $3,542,000 | – | 463,000 | +100.0% | 2.39% | – |
| ZFGN | New | ZAFGEN | $3,092,000 | – | 100,263 | +100.0% | 2.09% | – |
| TTPH | New | TETRAPHASE PHARMACEUTICALS | $2,970,000 | – | 74,803 | +100.0% | 2.01% | – |
| CTIC | New | CTI BIOPHARMA | $2,898,000 | – | 1,228,111 | +100.0% | 1.96% | – |
| RRM | New | RRSAT GLOBAL COMM NTWRK LTD | $2,890,000 | – | 401,424 | +100.0% | 1.95% | – |
| CRME | New | CARDIOME PHARMA CORP | $2,807,000 | – | 303,477 | +100.0% | 1.90% | – |
| 5100PS | New | VOLCANO CORPORATION | $2,743,000 | – | 153,436 | +100.0% | 1.85% | – |
| RXDX | New | IGNYTA | $2,530,000 | – | 369,360 | +100.0% | 1.71% | – |
| VRTX | New | VERTEX PHARMACEUTICALScall | $2,376,000 | – | 20,000 | +100.0% | 1.61% | – |
| RCPT | New | RECEPTOS | $2,299,000 | – | 18,768 | +100.0% | 1.55% | – |
| ENTA | New | ENANTA PHARMACEUTICALS | $2,264,000 | – | 44,528 | +100.0% | 1.53% | – |
| HZNP | New | HORIZON PHARMA PLC | $2,159,000 | – | 167,491 | +100.0% | 1.46% | – |
| VASC | New | VASCULAR SOLUTIONS | $2,023,000 | – | 74,494 | +100.0% | 1.37% | – |
| OFIX | New | ORTHOFIX INTL N V | $2,016,000 | – | 67,058 | +100.0% | 1.36% | – |
| CERS | New | CERUS | $1,924,000 | – | 308,282 | +100.0% | 1.30% | – |
| IRIX | New | IRIDEX | $1,797,000 | – | 208,933 | +100.0% | 1.21% | – |
| BBW | New | BUILD A BEAR WORKSHOP | $1,784,000 | – | 88,740 | +100.0% | 1.21% | – |
| EHTH | New | EHEALTH | $1,732,000 | – | 69,519 | +100.0% | 1.17% | – |
| FRSH | New | PAPA MURPHYS HLDGS | $1,632,000 | – | 140,462 | +100.0% | 1.10% | – |
| HSGX | New | HISTOGENICS | $1,505,000 | – | 136,804 | +100.0% | 1.02% | – |
| DEPO | New | DEPOMED | $1,465,000 | – | 90,958 | +100.0% | 0.99% | – |
| HPTX | New | HYPERION THERAPEUTICS | $1,451,000 | – | 60,462 | +100.0% | 0.98% | – |
| GWPH | New | GW PHARMACEUTICALS PLCcall | $1,354,000 | – | 20,000 | +100.0% | 0.92% | – |
| KIN | New | KINDRED BIOSCIENCES | $1,280,000 | – | 171,807 | +100.0% | 0.86% | – |
| FWP | New | FORWARD PHARMA A/Sspons adr | $1,265,000 | – | 60,730 | +100.0% | 0.86% | – |
| CERS | New | CERUScall | $1,248,000 | – | 200,000 | +100.0% | 0.84% | – |
| New | ARRAY BIOPHARMA INCnote 3.000% | $1,229,000 | – | 1,315,000 | +100.0% | 0.83% | – | |
| AMAG | New | AMAG PHARMACEUTICALS | $1,134,000 | – | 26,596 | +100.0% | 0.77% | – |
| PRTK | New | PARATEK PHARMACEUTICALS | $1,128,000 | – | 29,252 | +100.0% | 0.76% | – |
| CBMX | New | COMBIMATRIX CORPORATION | $1,101,000 | – | 853,278 | +100.0% | 0.74% | – |
| ZINCQ | New | HORSEHEAD HLDG | $1,086,000 | – | 68,577 | +100.0% | 0.73% | – |
| AGEN | New | AGENUS | $1,066,000 | – | 268,466 | +100.0% | 0.72% | – |
| BLCM | New | BELLICUM PHARMACEUTICALS | $1,054,000 | – | 45,750 | +100.0% | 0.71% | – |
| MOLGY | New | MOL GLOBAL INCspons adr | $1,036,000 | – | 339,575 | +100.0% | 0.70% | – |
| CRDC | New | CARDICA | $1,026,000 | – | 1,465,905 | +100.0% | 0.69% | – |
| HRTX | New | HERON THERAPEUTICS | $1,017,000 | – | 101,050 | +100.0% | 0.69% | – |
| INNL | New | INNOCOLL AGspons adr | $974,000 | – | 164,108 | +100.0% | 0.66% | – |
| CEMP | New | CEMPRAput | $940,000 | – | 40,000 | +100.0% | 0.64% | – |
| CASM | New | CAS MED SYS INC | $862,000 | – | 522,467 | +100.0% | 0.58% | – |
| GNVC | New | GENVEC | $738,000 | – | 354,784 | +100.0% | 0.50% | – |
| ATHN | New | ATHENAHEALTHput | $729,000 | – | 5,000 | +100.0% | 0.49% | – |
| NBIX | New | NEUROCRINE BIOSCIENCEScall | $704,000 | – | 31,500 | +100.0% | 0.48% | – |
| ATRS | New | ANTARES PHARMA | $598,000 | – | 232,762 | +100.0% | 0.40% | – |
| SQNM | New | SEQUENOM | $574,000 | – | 155,135 | +100.0% | 0.39% | – |
| NSPH | New | NANOSPHERE | $571,000 | – | 1,456,884 | +100.0% | 0.39% | – |
| CEMI | New | CHEMBIO DIAGNOSTICS | $571,000 | – | 146,099 | +100.0% | 0.39% | – |
| PSDV | New | PSIVIDA | $503,000 | – | 122,338 | +100.0% | 0.34% | – |
| P103PS | New | NPS PHARMACEUTICALScall | $358,000 | – | 10,000 | +100.0% | 0.24% | – |
| XNCR | New | XENCOR | $353,000 | – | 22,011 | +100.0% | 0.24% | – |
| OXM | New | OXFORD IMMUNOTEC GLOBAL PLC | $337,000 | – | 24,742 | +100.0% | 0.23% | – |
| P103PS | New | NPS PHARMACEUTICALS | $286,000 | – | 8,000 | +100.0% | 0.19% | – |
| VCYT | New | VERACYTE | $280,000 | – | 29,024 | +100.0% | 0.19% | – |
| INSM | New | INSMED | $203,000 | – | 13,154 | +100.0% | 0.14% | – |
| New | TRILLIUM THERAPEUTICS | $171,000 | – | 19,000 | +100.0% | 0.12% | – | |
| CYHHZ | New | COMMUNITY HEALTH SYS INC NEWright 01/27/2016 | $74,000 | – | 2,963,721 | +100.0% | 0.05% | – |
| ASMB | New | ASSEMBLY BIOSCIENCES | $30,000 | – | 3,800 | +100.0% | 0.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-02-13
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
| IRIDEX CORP | 20 | Q3 2019 | 8.1% |
| ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
| IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
| VERACYTE INC | 19 | Q3 2019 | 10.1% |
| ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
| XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
| CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
| APELLIS PHARMACEUTICALS INC | 17 | Q3 2023 | 18.4% |
| KURA ONCOLOGY INC. COMMON STOCK | 17 | Q3 2023 | 8.1% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
| Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
| IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
| CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.